Back to search

Article

A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron

2022-01-04

Abstract excerpt

Bispecific antibodies have emerged as a promising strategy for curtailing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report highlights RBT-0813 (also known as TB493-04), a synthetic, humanized, receptor-binding domain (RBD)-targeted bispecific antibody that retains picomolar affinity to the Spike (S) trimers of all major variants of concern and neutralizes both SARS-CoV-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
749b5fb4-aa74-5aa0-8af1-2b977bc17e80
DOI
10.1101/2022.01.04.474803
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and OmicronDOI 10.1101/2022.01.04.474803
A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of ConcernSemantic proximity
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodiesSemantic proximity
Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineagesSemantic proximity
A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of ConcernSemantic proximity
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsSemantic proximity
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617Semantic proximity
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617Semantic proximity
Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concernSemantic proximity
Combating the SARS-CoV-2 Omicron variant with non-Omicron neutralizing antibodiesSemantic proximity
Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralizationSemantic proximity
A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variantsSemantic proximity
A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administrationSemantic proximity
Select a neighboring publication to make it the new centre.